How to buy NGM Biopharmaceuticals stock - 10 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy NGM Biopharmaceuticals stock

Own NGM Biopharmaceuticals stock in just a few minutes.

NGM Biopharmaceuticals, Inc is a biotechnology business based in the US. NGM Biopharmaceuticals shares (NGM) are listed on the NASDAQ and all prices are listed in US Dollars. NGM Biopharmaceuticals employs 210 staff and has a trailing 12-month revenue of around USD$87.4 million.

How to buy shares in NGM Biopharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for NGM Biopharmaceuticals. Find the stock by name or ticker symbol: NGM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until NGM Biopharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of NGM Biopharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of NGM Biopharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

NGM Biopharmaceuticals share price

Use our graph to track the performance of NGM stocks over time.

NGM Biopharmaceuticals shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$14.7 - USD$32.12
50-day moving average USD$28.6144
200-day moving average USD$24.4679
Wall St. target priceUSD$39.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.457

Buy NGM Biopharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy NGM Biopharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NGM Biopharmaceuticals financials

Revenue TTM USD$87.4 million
Gross profit TTM USD$-76,604,000
Return on assets TTM -18.3%
Return on equity TTM -33.56%
Profit margin -117.31%
Book value $3.967
Market capitalisation USD$2 billion

TTM: trailing 12 months

Shorting NGM Biopharmaceuticals shares

There are currently 2.2 million NGM Biopharmaceuticals shares held short by investors – that's known as NGM Biopharmaceuticals's "short interest". This figure is 25.3% up from 1.7 million last month.

There are a few different ways that this level of interest in shorting NGM Biopharmaceuticals shares can be evaluated.

NGM Biopharmaceuticals's "short interest ratio" (SIR)

NGM Biopharmaceuticals's "short interest ratio" (SIR) is the quantity of NGM Biopharmaceuticals shares currently shorted divided by the average quantity of NGM Biopharmaceuticals shares traded daily (recently around 250242.55813953). NGM Biopharmaceuticals's SIR currently stands at 8.6. In other words for every 100,000 NGM Biopharmaceuticals shares traded daily on the market, roughly 8600 shares are currently held short.

However NGM Biopharmaceuticals's short interest can also be evaluated against the total number of NGM Biopharmaceuticals shares, or, against the total number of tradable NGM Biopharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NGM Biopharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 NGM Biopharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0669% of the tradable shares (for every 100,000 tradable NGM Biopharmaceuticals shares, roughly 67 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NGM Biopharmaceuticals.

Find out more about how you can short NGM Biopharmaceuticals stock.

NGM Biopharmaceuticals share dividends

We're not expecting NGM Biopharmaceuticals to pay a dividend over the next 12 months.

NGM Biopharmaceuticals share price volatility

Over the last 12 months, NGM Biopharmaceuticals's shares have ranged in value from as little as $14.7 up to $32.12. A popular way to gauge a stock's volatility is its "beta".

NGM.US volatility(beta: 2.01)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NGM Biopharmaceuticals's is 2.0096. This would suggest that NGM Biopharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.

NGM Biopharmaceuticals overview

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trial for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase Ib clinical trials to inhibit growth differentiation factor GDF15 levels on cancer anorexia/cachexia syndrome; NGM621, an antibody in Phase II clinical trials for the treatment of geographic atrophy; and NGM707 and NGM438, which are in preclinical investigational studies for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site